NOXXON Pharma NV has reported a promising response from a patient with metastatic pancreatic cancer to its RNA oligonucleotide drug that is intended to fight cancer by targeting the tumour microenvironment. The company gave the update on 16 May at the BioEquity Europe conference in Belgium.
